// App-Quantinova.ai

: Clinical efficacy and biomarker analysis of pucotenlimab (HX008) in patients with previously treated advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A single-arm, multicenter, phase 2 study.

Researchers

Presenter

  • Bo Zhang

Principal Investigators

  • Suxia Luo

  • Xianli Yin

  • Enxiao Li

  • Hui Wang

  • Yifu He

  • Zhihui Liu

  • Qingxia Fan

  • Xinjun Liang

  • Yongqian Shu

  • Yunpeng Liu

  • Nong Xu

  • Shu Zhang

  • Zhixiang Zhuang

  • Jingdong Zhang

  • Xiaoge Kou

  • Fen Wang

  • Xiaodong Zhu

  • Jing Huang

Medical Centers

  • Department of Ophthalmology, The Second Affiliated Hospital of Soochow University, SuZhou, JiangSu, China

  • Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Tianjin People's Hospital, Tianjin, China

  • Shandong Cancer Hospital, Jinan, China

  • Liaoning Cancer Hospital, Shenyang, Liao Ning, China

  • Henan Cancer Hospital, Zhengzhou, China

  • First Affiliated Hospital of Chengdu University, Chengdu, China

  • Department of Rheumatology, Jiangsu Provincial Peopl-s Hospital, Nanjing, China

  • Hubei Cancer Hospital, Wuhan, China

  • The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China

  • The First Affiliated Hospital of Bengbu Medical College, Bengbu, China

  • First Affiliated Hospital of Xi-An Jiaotong University, Xi an, China

  • The Fist Affiliated Hospital of China Medical University, Shenyang, China

  • Fudan University Shanghai Cancer Center, Shanghai, China

  • Anhui Provincial Cancer Hospital, Hefei, China

  • Peking University Shenzhen Hospital, Shenzhen, China.

  • Tianjin Medical University Cancer Hospital, Tianjin, China

  • Hunan Cancer Hospital, Changsha, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Neutrophil lymphocyte ratio

  • Programmed death-ligand 1

  • Microsatellite instability-high

  • Tumor mutational burden

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Single Arm

  • Multicenteric

Phase

  • II

Study Id's

  • NCT03704246

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved